Computed tomography measured epicardial adipose tissue and psoas muscle attenuation: new biomarkers to predict major adverse cardiac events (MACE) and mortality in patients with heart disease and critically ill patients. Part I: Epicardial adipose tissue
Why the study?
Epicardial adipose tissue has been extensively studied as a marker for major adverse cardiovascular events, warranting a review of its biological pathways, imaging modalities, and clinical prognostic utility.
Does epicardial adipose tissue (EAT) assessment predict major adverse cardiovascular events (MACE) in patients with heart disease and critically ill patients?
Design
Review
Authors
Discussion
Loading...
Member takes
Overview
EAT imaging may refine MACE risk stratification in cardiac patients; leaves open its incremental value and need for prospective validation.
Structured PICO
Does epicardial adipose tissue (EAT) assessment predict major adverse cardiovascular events (MACE) in patients with heart disease and critically ill patients?
P
Population
Patients with heart disease and critically ill patients
I
Intervention
Assessment of epicardial adipose tissue (EAT) using imaging modalities (echocardiography, cardiac CT, and cardiac magnetic resonance)
O
Outcome
Prediction of major adverse cardiovascular events (MACE) and mortalitysurrogate
Epicardial adipose tissue measured by imaging modalities is a promising biomarker for predicting major adverse cardiovascular events across various cardiac conditions.
Cite This Study
Walpot et al. (2023) studied this question.